$ALNA News

Last published 4y ago

4y agoALNAAllena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney DiseaseGlobeNewswireNEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral
4y agoALNAAllena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitGlobeNewswireNEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and s
4y agoALNAAllena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitGlobeNewswireNEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and s
4y agoALNA CPNG MITO RIDE+1Thinking about buying stock in Stealth BioTherapeutics, Allena Pharmaceuticals, Salarius Pharmaceuticals, Coupang, or Lordstown Motors?PR NewswireNEW YORK, May 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, ALNA, SLRX, CPNG, and RIDE. T
4y agoALNAAllena Pharmaceuticals Announces $2.8 Million Registered Direct OfferingGlobeNewswireNEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and s
4y agoALNA CEI HYMC NILE+1Thinking about buying stock in Bitnile, Camber Energy, Nio, Hycroft Mining, or Allena Pharmaceuticals?PR NewswireNEW YORK, March 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NILE, CEI, NIO, HYMC, and ALNA. T
4y agoALNA BP CCL NLSP+1Thinking about buying stock in Allena Pharmaceuticals, Carnival Corp, Oragenics, NLS Pharmaceutics, or BP?PR NewswireNEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALNA, CCL, OGEN, NLSP, and BP. To
4y agoALNAAllena Pharmaceuticals Provides Clinical and Corporate UpdateGlobeNewswireALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia
4y agoALNAScintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets - NCT05168683ClinicalTrials.govScintigraphic images to detect time and onset and transit time of radiolabel release, Incidence of Adverse Events
4y agoALNAVersantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEOBusiness Wire- Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan
4y agoALNAAllena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare ConferenceGlobeNewswireNEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeut
5y agoALNAAllena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate ProgressGlobeNewswireALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA Two Phase 2a trials for ALLN-34
5y agoALNA CRTO ICPT PACB+1Thinking about buying stock in PROG Holdings, Criteo SA, Pacific Biosciences, Allena Pharmaceuticals, or Intercept Pharmaceuticals?PR NewswireNEW YORK, Nov. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRG, CRTO, PACB, ALNA, and ICPT. To
5y agoALNAAllena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney DiseaseGlobeNewswire- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract - - Patients with gout and CKD have a serious condition with an unmet need for urate-lowering–therapies – -Two Phase 2a studies currently enrolling patien
5y agoALNAAllena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346GlobeNewswire- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data expected in late 2021 or early 2022 - NEWTON,
5y agoALNAAllena Pharmaceuticals to Participate in H.C. Wainwright's 23rd Annual Global Investment ConferenceGlobeNewswireNEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeu
5y agoALNAAllena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate ProgressGlobeNewswireALLN-346 well-tolerated in recently completed Phase 1b study; first patients dosed in Phase 2a program for gout and chronic kidney disease; initial data expected in Q4 2021 June KOL webinar highlighted the unmet need in gout and potential for ALLN-346
5y agoALNAAllena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare ConferenceGlobeNewswireNEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and s
5y agoALNAAllena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with
5y agoALNA BEKE LI TLRYThinking about buying stock in Tilray, KE Holdings, Li Auto, Allena Pharmaceuticals, or New York Community Bancorp?PR NewswireNEW YORK, July 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLRY, BEKE, LI, ALNA, and NYCB. To
5y agoALNAAllena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewswireNEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and s
5y agoALNAAllena Pharmaceuticals Provides Update on Clinical Development ProgramsGlobeNewswire-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021- -Reloxaliase advancing in URIROX-2 Pivotal Phase 3 study; revised interim analysis now targeted for Q1 2
5y agoALNAAllena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare ConferenceGlobeNewswireNEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients wit
5y agoALNAAllena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEWTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with
5y agoALNAAllena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with
5y agoALNAAllena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney DiseaseGlobeNewswireNEWTON, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare a
5y agoALNAAllena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswire-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 ---- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expected 3Q 2021 ---- On-track to initiate Phase 2a program
5y agoALNAAllena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEWTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with r
5y agoALNAAllena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireNEWTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing...
5y agoALNAAllena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of DirectorsGlobeNewswireNEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAStudy 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) - NCT04829435ClinicalTrials.govIncidence of Treatment Emergent Adverse Events (TEAEs), Serum ALLN-346
5y agoALNAAllena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewswire-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a...
5y agoALNAAllena Pharmaceuticals to Present at Upcoming Investor Conferences in MarchGlobeNewswireNEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial OfficerGlobeNewswireNEWTON, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals to Present at Upcoming Investor Conferences in JanuaryGlobeNewswireNEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 MillionGlobeNewswireNEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals Announces $10.0 Million Bought Deal OfferingGlobeNewswireNEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical OfficerGlobeNewswireNEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
5y agoALNAAllena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346GlobeNewswire-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated ---- Non-Absorption of ALLN-346 Demonstrated ---- Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept...
5y agoALNAAllena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewswireNEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
6y agoALNAAllena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire-- Presented Data at 53rd Annual Meeting of the American Society of Nephrology (ASN) Highlighting Consistent Treatment Effects Across Phase 2 and 3 Clinical Trials of Reloxaliase in Enteric...
6y agoALNAAllena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in NovemberGlobeNewswireNEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
6y agoCMRX GSK ALNANoveome Biotherapeutics, Inc. Announces New Appointments to its Board of DirectorsBusiness WirePITTSBURGH, Pa.--(BUSINESS WIRE)--Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed M. Michelle Berrey, M.D., M.P.H. and Annamaria T. Kausz, M.D., M.S. as members of the company’s Board of Directors.
6y agoALNAAllena Pharmaceuticals Appoints Ann Miller, M.D. to its Board of DirectorsGlobeNewswireNEWTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
6y agoALNAAllena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax VenturesGlobeNewswire-- Extends Allena’s Cash Runway into 4Q 2021 ---- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc....
6y agoALNAAllena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney DiseaseGlobeNewswireNEWTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
6y agoALNAAllena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in SeptemberGlobeNewswireNEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
6y agoALNAAllena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of...
6y agoALNAAllena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireNEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
6y agoALNAAllena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 MillionGlobeNewswireNEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...